Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual
Go back to Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual| (NASDAQ: RVMD) | Delayed: 169.77 +0.26 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $169.51 | 52 Week High | $ | |||
| Open | $170.50 | 52 Week Low | $ | |||
| Day High | $170.65 | P/E | N/A | |||
| Day Low | $166.43 | EPS | $ | |||
| Volume | 3,625,693 | |||||
